《大行報告》摩通下調創科(00669.HK)目標價至128元 評級「增持」
摩根大通發表報告指,雖然投資者仍繼續討論創科(00669.HK)過去的毛利率表現,及今年較同業為佳的指引,但繼續看到其基本面可推動股價,包括集團是無線電池供電領域的先行者、更專注於專業細分市場,以及對各種終端需求有多元化的垂直業務,此等因素都可降低其盈利對全球經濟放緩的敏感度。
該行提到,創科去年的自由現金流有明顯改善,由於集團將重點放於營運資本正常化,預計此情況將於今年持續。
摩通下調創科股份目標價,由130元降至128元,評級維持「增持」,並下調集團今年至2025年稅後純利預測介乎5%至8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.